Exclusive Summary

• - Targets a 254M CHB population with only ~3% treatment coverage, enabling rapid entry into high-prevalence markets.
• - Once-daily 45 mg liver-targeted nucleotide analog; China clinical data suggest TDF-comparable antiviral efficacy with better renal/bone safety markers, fitting patients at renal or bone risk.
• - Minimal global in-class competition and virtually no generics, offering first-to-market/sole-distributor potential and strong differentiation.
• - While WHO first-line remains TDF/TAF/ETV and pradefovir is not in the WHO EML, it can serve as an alternative for TDF-intolerant or renal/bone-risk patients and compete with TAF on access and price.
• - Use ICH-CTD dossier and China development experience to pursue reliance pathways, prioritizing Asia, Africa, and MENA with Distribution partners.